All In Biotech

NDA 211349 · Astellas

Xospata

Gilteritinib Fumarate · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 28, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

67

12 Phase 3, 28 recruiting

FAERS reports

4,079

3,848 serious, 1,051 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DIFFERENTIATION SYNDROME Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution. ( 5.1 ,...

What it is approved for

From the label in effect Oct 1, 2026.

XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 ) 1.1 Relapsed or Refractory Acute Myeloid Leukemia XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.

Mechanism: Gilteritinib is a small molecule that inhibits multiple receptor tyrosine kinases, including FMS-like tyrosine kinase 3 (FLT3). Gilteritinib demonstrated the ability to inhibit FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, tyrosine kinase domain mutations (TKD) FLT3-D835Y and FLT3-ITD-D835Y, and it induced apoptosis in leukemic cells expressing FLT3-ITD.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XOSPATA · GILTERITINIB FUMARATE EQ 40MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gilteritinib" as an intervention, any sponsor and status, largest first.

All 67 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use508
  • acute myeloid leukaemia342
  • myelosuppression312
  • platelet count decreased298
  • pneumonia282
  • death273
  • pyrexia261
  • product use issue254
  • febrile neutropenia252
  • acute myeloid leukaemia recurrent180
  • cytopenia167
  • infection161

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20174
20188
2019186
2020359
2021578
2022628
2023619
2024599
2025645
2026452

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xospata (Gilteritinib Fumarate)

2024 spending

$106M

Beneficiaries

1,048

4,809 claims

Per beneficiary

$101,561

$303.80 per unit

View as table
YearSpending
2020$58,718,494
2021$70,195,773
2022$75,577,732
2023$89,759,419
2024$106,436,061

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.